Clinical Trials Browser

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT06250972 2025-08-07

PTCA199-11

Phase 3 Recruiting

210 enrolled

Gastrointestinal

Pancreatic Adenocarcinoma

NCT04879368 2025-07-17

INTEGRATEIIb

Phase 3 Active not recruiting

450 enrolled

Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT02885753 2025-07-09

OSCAR

Phase 3 Recruiting

348 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT04861558 2025-05-30

EFFIPEC

Phase 3 Recruiting

213 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04415853 2025-05-18

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3 Recruiting

416 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Phase 3 Completed

324 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

Phase 3 Completed

673 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06899477 2025-03-28

Pre-Operative Treatment in REseCTable COlon CanceR

Phase 3 Not yet recruiting

714 enrolled

Gastrointestinal

Colonic Neoplasms

NCT01167725 2024-12-27

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Phase 3 Terminated

340 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06496048 2024-12-12

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Phase 3 Recruiting

180 enrolled

Thoracic

Small Cell Lung Carcinoma

Clinical Trials

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

MEND-IT II

TroFuse-020

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

MK-3475-C66

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

TRIBE-C

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

SOLARIS

FOBEAR

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

TroFuse-015

innovaTV 301

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

LAP100

NB-NK-2026

Beacon-BTC

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

GRECCAR8

AIO-KRK-0418

RASolute 302

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

AtezoTRIBE2

NEXT-REGIRI

IROCAS

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

CheckMate 8HW

LIBImAb

LEFT-PANC

The Sagittarius Trial

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

PTCA199-11

INTEGRATEIIb

OSCAR

EFFIPEC

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

AIO-KRK-0114

Pre-Operative Treatment in REseCTable COlon CanceR

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC